Press Release

Dr. Djurhuus commented, “I am excited to join Clinical ink at a time when the convergence of digital health, clinical science, and patient‑centric data capture is creating new opportunities. I look forward to helping advance a disease management solution that delivers meaningful impact for patients while strengthening evidence generation for biopharma partners.”

Members from multiple therapeutic areas will incorporate the patient voice into clinical trial technology design.

Clinical ink announces an integrated suite of eClinical tools for cardiometabolic clinical trials.

Clinical ink is expanding its patient engagement suite with the inclusion of the SPUR™ behavioral diagnostic tool created by Observia.